Navigation Links
Alabama's top cancer center earns $11.5 million renewal of its breast cancer SPORE
Date:10/8/2007

BIRMINGHAM, Ala. As National Breast Cancer Awareness Month, October has been a key time to recognize the strides made in breast cancer prevention, detection and treatment, and to press forward in the battle against the disease.

The National Institutes of Health (NIH) has recognized the University of Alabama at Birminghams (UAB) commitment to cancer research by renewing a major grant to support groundbreaking breast cancer science and discovery. NIH has awarded the UAB Comprehensive Cancer Center an $11.5 million renewal grant of its Specialized Program of Research Excellence (SPORE) in breast cancer from the National Cancer Institute.

The UAB breast cancer SPORE is among 11 such projects funded nationally. Since its inception more than five years ago, the UAB program has grown into one of the most productive and highest-ranked efforts to combat the disease.

"Theres no question this grant is a fantastic honor, and a major recognition of our award-winning womens cancer care," said Cancer Center Director Edward Partridge, M.D. "What this means for the women of Alabama and the region is that our breast health program is stronger than ever. It also means that women who come to UAB with breast cancer, or risk factors for the disease, are potentially eligible for leading-edge treatments."

The $11.5 million grant will focus primarily on experimental compounds and cellular targets that have shown promise in preventing, slowing or effectively treating breast cancer. Three of the four main projects involve targeted therapies and anti-cancer compounds that were discovered or developed in the basic science laboratories of UAB, and will soon be tested here.

"The great fundamental strength of this SPORE is seizing on translational research taking a finding from the lab, and then moving it into clinical testing to see if it helps prevent, treat or conquer breast cancer," said Kirby I. Bland, M.D., chair of the UAB Department of Surgery and principal investigator of UABs breast cancer SPORE. Albert LoBuglio, M.D., is the co-principal investigator.

Limited federal funds for cancer research means that NIH-backed projects, particularly SPORE grants, must demonstrate potential for use in patients. "Each of these UAB breast cancer projects have already shown great potential for reducing cancer burden," Bland said.

The grant renewal will fund these four primary projects:

  • Anti-Cancer Antibody Targets DR5. Testing will continue for an experimental anti-cancer agent called TRA-8 in patients whose breast cancer has failed to respond to available therapies. TRA-8 is a monoclonal antibody developed at UAB. Studies show it targets a tumor cell death receptor (DR5) and induces cancer-cell death, while sparing healthy cells. Principal investigators are Tong Zhou, M.D., Albert LoBuglio, M.D. and Donald Buschbaum, Ph.D.
     
  • Retinoids for Chemoprevention. A Phase I clinical trial in humans will examine the experimental compound UAB30 to see if it can prevent breast-cancer recurrence. Developed and patented by UAB scientists years ago, UAB30 is a retinoid, which is a synthetic vitamin A-like compound with proven anti-cancer properties in animals. Other studies will look at retinoids to prevent hormone-resistant breast tumors in animals, or to see if retinoids can prevent and treat other types of cancers. Principal investigators are Donald Muccio, Ph.D., Clinton Grubbs, Ph.D. and Helen Krontiras, M.D.
     
  • KLF4 Cancer Gene Biomarkers. Research is underway to determine if targeting a UAB-discovered cancer gene called KLF4 with drugs can help treat certain aggressive forms of breast cancer. Also, researchers are looking at whether testing for KLF4 genes in breast tissue is a worthwhile predictor for a womans risk of getting cancer. Principal investigators are J. Michael Ruppert, M.D., Ph. D. and Kirby I. Bland, M.D.
     
  • Gamma/Delta T-cell Cancer Therapy. Testing is ongoing for an anti-cancer agent that mirrors the immune response of human gamma/delta T-cells when they detect a bodily invader. These specific cells are rare, comprising only five percent of all T-cells in the body, but theyre considered one of the bodys most powerful defenses against cancer. UAB has found a way to grow and purify these T-cells in the lab, and now plans to test their anti-cancer potential in breast tumors. Principal investigators are Richard Lopez, M.D. and Kurt Zinn, D.V.M., Ph.D.
     

'/>"/>
Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Vitamin B12 can help in detecting cancers
6. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
7. Consensus on "Combination Therapy" for Breast Cancer
8. Cancers of Colon & Rectum linked to Cigarette Smoking
9. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
10. The Cancer Rumour mill working over time
11. Want skin cancer? Please have a cigarette
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
Breaking Medicine Technology: